Drug Approval | April 21, 2022
Boehringer Ingelheim launches RenuTend to heal ligament injuries in horses
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
The data driven fertility company helps increase the success rate of fertility treatments
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Both companies have been selected for stand-by production by German government
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact
Subscribe To Our Newsletter & Stay Updated
